Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort

References

• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35–45.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210–21.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009;60:2272–83.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805–11.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.
   PubMed Web of Science ®Google Scholar
• Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614–24.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar
• Lundquist L. Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv Ther 2007; 24:333–45.
   PubMed Web of Science ®Google Scholar
• Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003;48:3308–19.
   PubMed Web of Science ®Google Scholar
• Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 2007;66:1184–9.
   PubMed Web of Science ®Google Scholar
• Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005;23:795–800.
   PubMed Web of Science ®Google Scholar
• Wick MC, Erenstam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005;34:353–8.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 2004;51:301–2.
   PubMed Web of Science ®Google Scholar
• Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 2003;30:2315–18.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13–20.
   PubMed Web of Science ®Google Scholar
• Gomez-Puerta JA, Sanmarti R, Rodriguez-Cros JR, Canete JD. Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann Rheum Dis 2004;63:896.
   PubMed Web of Science ®Google Scholar
• Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098–102.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007;66:849–51.
   PubMed Web of Science ®Google Scholar
• Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417–23.
   PubMed Web of Science ®Google Scholar
• Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006;45:1121–4.
   PubMed Web of Science ®Google Scholar
• Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387–93.
   PubMed Web of Science ®Google Scholar